RNVU1-17

Across TCGA pan-cancer cohorts, RNVU1-17 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNVU1-17 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNVU1-17 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNVU1-17 expression acts as an unfavorable survival marker, although some lineages such as SARC show a favorable association.

LIHC, UCEC, and BLCA are the cancer types where RNVU1-17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.179	0.786	<.001	72	view →
UCEC	DFS	Tertile	III,IV	0.656	0.804	.014	42	view →
BLCA	OS	Tertile	IV	0.074	0.599	<.001	36	view →
OV	OS	Tertile	All	0.621	0.706	.011	18	view →
BRCA	DFS	Tertile	All	0.847	0.951	.016	12	view →
LGG	DFS	Tertile	All	0.576	0.747	.014	12	view →
SARC	DFS	Tertile	All	0.869	0.494	.009	9	view →
SKCM	OS	Tertile	All	0.121	0.400	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RNVU1-17–LIHC (OS)

Open the LIHC breakdown →